Review



ralstonia eutropha iam 12368  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    ATCC ralstonia eutropha iam 12368
    Ralstonia Eutropha Iam 12368, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 29 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ralstonia eutropha iam 12368/product/ATCC
    Average 92 stars, based on 29 article reviews
    ralstonia eutropha iam 12368 - by Bioz Stars, 2025-12
    92/100 stars

    Images



    Similar Products

    92
    ATCC ralstonia eutropha iam 12368
    Ralstonia Eutropha Iam 12368, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ralstonia eutropha iam 12368/product/ATCC
    Average 92 stars, based on 1 article reviews
    ralstonia eutropha iam 12368 - by Bioz Stars, 2025-12
    92/100 stars
      Buy from Supplier

    93
    Novus Biologicals anti rabbit zdhhc9
    Anti Rabbit Zdhhc9, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti rabbit zdhhc9/product/Novus Biologicals
    Average 93 stars, based on 1 article reviews
    anti rabbit zdhhc9 - by Bioz Stars, 2025-12
    93/100 stars
      Buy from Supplier

    90
    Proteintech antibodies against pinx1 12368-1-ap
    Antibodies Against Pinx1 12368 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against pinx1 12368-1-ap/product/Proteintech
    Average 90 stars, based on 1 article reviews
    antibodies against pinx1 12368-1-ap - by Bioz Stars, 2025-12
    90/100 stars
      Buy from Supplier

    93
    Proteintech pinx1
    A Volcano plot of proximity proteomics of a PARP1-TurboID against a TurboID control. B Volcano plot of proximity proteomics of a PARP1-TurboID with or without biotin treatment. The p -values were calculated by a two-sample t -test. Curves indicate a minimal fold change >2, <−2, and 5% FDR calculated by Perseus. Proteins that show significant proximity to PARP1 are depicted in black dots, while proteins that show significant proximity to PARP1 both in ( A ) and in ( B ) are marked with red stars. C Venn diagram of proximity proteins in ( A ) and ( B ). D – F Exogenous co-IP to confirm the binding between <t>PINX1/UTP14A/ZNF24</t> and PARP1. PARP1-Myc and PINX1/UTP14A/ZNF24-FLAG constructs were co-transfected into HEK293T cells, and IP of whole cell lysates with anti-FLAG agarose beads was performed. G – I Reciprocal exogenous co-IP to confirm the binding between PINX1/UTP14A/ZNF24 and PARP1. PARP1-Myc and PINX1/UTP14A/ZNF24-FLAG constructs were co-transfected into HEK293T cells, and IP of whole cell lysates with anti-Myc agarose beads was performed.
    Pinx1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pinx1/product/Proteintech
    Average 93 stars, based on 1 article reviews
    pinx1 - by Bioz Stars, 2025-12
    93/100 stars
      Buy from Supplier

    90
    DSMZ dsm 12368
    A Volcano plot of proximity proteomics of a PARP1-TurboID against a TurboID control. B Volcano plot of proximity proteomics of a PARP1-TurboID with or without biotin treatment. The p -values were calculated by a two-sample t -test. Curves indicate a minimal fold change >2, <−2, and 5% FDR calculated by Perseus. Proteins that show significant proximity to PARP1 are depicted in black dots, while proteins that show significant proximity to PARP1 both in ( A ) and in ( B ) are marked with red stars. C Venn diagram of proximity proteins in ( A ) and ( B ). D – F Exogenous co-IP to confirm the binding between <t>PINX1/UTP14A/ZNF24</t> and PARP1. PARP1-Myc and PINX1/UTP14A/ZNF24-FLAG constructs were co-transfected into HEK293T cells, and IP of whole cell lysates with anti-FLAG agarose beads was performed. G – I Reciprocal exogenous co-IP to confirm the binding between PINX1/UTP14A/ZNF24 and PARP1. PARP1-Myc and PINX1/UTP14A/ZNF24-FLAG constructs were co-transfected into HEK293T cells, and IP of whole cell lysates with anti-Myc agarose beads was performed.
    Dsm 12368, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dsm 12368/product/DSMZ
    Average 90 stars, based on 1 article reviews
    dsm 12368 - by Bioz Stars, 2025-12
    90/100 stars
      Buy from Supplier

    93
    Proteintech pinx1 antibody
    <t> PINX1 </t> expression and correlation between papillary and anaplastic thyroid carcinoma
    Pinx1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pinx1 antibody/product/Proteintech
    Average 93 stars, based on 1 article reviews
    pinx1 antibody - by Bioz Stars, 2025-12
    93/100 stars
      Buy from Supplier

    Image Search Results


    A Volcano plot of proximity proteomics of a PARP1-TurboID against a TurboID control. B Volcano plot of proximity proteomics of a PARP1-TurboID with or without biotin treatment. The p -values were calculated by a two-sample t -test. Curves indicate a minimal fold change >2, <−2, and 5% FDR calculated by Perseus. Proteins that show significant proximity to PARP1 are depicted in black dots, while proteins that show significant proximity to PARP1 both in ( A ) and in ( B ) are marked with red stars. C Venn diagram of proximity proteins in ( A ) and ( B ). D – F Exogenous co-IP to confirm the binding between PINX1/UTP14A/ZNF24 and PARP1. PARP1-Myc and PINX1/UTP14A/ZNF24-FLAG constructs were co-transfected into HEK293T cells, and IP of whole cell lysates with anti-FLAG agarose beads was performed. G – I Reciprocal exogenous co-IP to confirm the binding between PINX1/UTP14A/ZNF24 and PARP1. PARP1-Myc and PINX1/UTP14A/ZNF24-FLAG constructs were co-transfected into HEK293T cells, and IP of whole cell lysates with anti-Myc agarose beads was performed.

    Journal: Cell Death & Disease

    Article Title: PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells

    doi: 10.1038/s41419-024-07009-6

    Figure Lengend Snippet: A Volcano plot of proximity proteomics of a PARP1-TurboID against a TurboID control. B Volcano plot of proximity proteomics of a PARP1-TurboID with or without biotin treatment. The p -values were calculated by a two-sample t -test. Curves indicate a minimal fold change >2, <−2, and 5% FDR calculated by Perseus. Proteins that show significant proximity to PARP1 are depicted in black dots, while proteins that show significant proximity to PARP1 both in ( A ) and in ( B ) are marked with red stars. C Venn diagram of proximity proteins in ( A ) and ( B ). D – F Exogenous co-IP to confirm the binding between PINX1/UTP14A/ZNF24 and PARP1. PARP1-Myc and PINX1/UTP14A/ZNF24-FLAG constructs were co-transfected into HEK293T cells, and IP of whole cell lysates with anti-FLAG agarose beads was performed. G – I Reciprocal exogenous co-IP to confirm the binding between PINX1/UTP14A/ZNF24 and PARP1. PARP1-Myc and PINX1/UTP14A/ZNF24-FLAG constructs were co-transfected into HEK293T cells, and IP of whole cell lysates with anti-Myc agarose beads was performed.

    Article Snippet: Following primary antibodies were used for western blot analysis in this study: FLAG (GNI, Cat# GNI4110-FG), Myc (Cell Signaling, Cat# 2276S), GAPDH (Proteintech, Cat# 10494-1-AP-100UL), γ-tubulin (Sigma-Aldrich, Cat# T6557), Vinculin (Sigma, Cat# V4505), PINX1 (Proteintech, Cat# 12368-1-AP-50ul), PAR (R&D, Cat# 4335-MC-100), PARP1 (Cell Signaling, Cat# 9542S), Lamin B1 (Bimake, Cat# A5106), β-tubulin (Eastacres Biologicals, Cat# MaTub-b), XRCC1 (Bimake, Cat# A5299), PCNA (Santa Cruz, Cat# sc-7907), γH2AX (Millipore, Cat# 05-636), Histone H3 (Bimake, Cat# A5885), Lamin B (Santa Cruz, Cat# sc-6216), FLAG (Abclonal, Cat# AE063), Myc (Abclonal, Cat# AE070), UTP14A (Abclonal, Cat# A5960), ZNF24 (Santa Cruz, Cat# sc-393359), ATM (Beyotime, Cat# AF1399), ATM p-Ser1981 (Abclonal, Cat# AP0008), ATR (Beyotime, Cat# AF6267), ATR p-Thr1989 (GeneTex, Cat# GTX637560-S), GFP (BBI, Cat# D110008), mCherry (OriGene, Cat# AB8181-200).

    Techniques: Control, Co-Immunoprecipitation Assay, Binding Assay, Construct, Transfection

    A Sensitivity of WT and PINX1 KO Hela cells to Talazoparib. PINX1 KO -1 and PINX1 KO -2 represent two distinct PINX1 KO single clones derived from WT Hela cells. B , C Sensitivity of indicated Hela cell lines to Talazoparib ( B ) or Olaparib ( C ). WT_EV, PINX1 KO _EV, PINX1 KO _PINX1, and PINX1 KO _PINX1[1-253aa] are stable cell lines reconstituted with corresponding empty vector (EV), full-length PINX1 or TID domain truncated PINX1 (PINX1[1-253aa]) using lentivirus. D – F Sensitivity of PINX1 knockdown OVCAR8 ( D ), OC316 ( E ), and BEL7404 ( F ) cells to Talazoparib. shLuc was used as a non-targeted control. A – F The cell lines were treated with indicated drugs and allowed to grow for 6 days. Cell viability was assessed by the Cell Titer-Glo assay. Surviving fractions were calculated relative to control untreated cells. All dots and error bars represent means ± SDs from at least three independent experiments. Statistical analyses were performed using two-way ANOVA testing. G Schematic illustration of the treatment protocol in the OC316 xenograft model. H Tumor growth curves of OC316 xenograft tumor-bearing mice for each indicated group ( n = 5). Significance was determined by an unpaired t-test at the endpoint. Error bars show ±1 SEM. I Tumor weight measurement at the endpoint of ( G ). Significance was determined by an unpaired t -test. Error bars show ±1 SD. J Images of dissected tumor tissues for each indicated group. ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells

    doi: 10.1038/s41419-024-07009-6

    Figure Lengend Snippet: A Sensitivity of WT and PINX1 KO Hela cells to Talazoparib. PINX1 KO -1 and PINX1 KO -2 represent two distinct PINX1 KO single clones derived from WT Hela cells. B , C Sensitivity of indicated Hela cell lines to Talazoparib ( B ) or Olaparib ( C ). WT_EV, PINX1 KO _EV, PINX1 KO _PINX1, and PINX1 KO _PINX1[1-253aa] are stable cell lines reconstituted with corresponding empty vector (EV), full-length PINX1 or TID domain truncated PINX1 (PINX1[1-253aa]) using lentivirus. D – F Sensitivity of PINX1 knockdown OVCAR8 ( D ), OC316 ( E ), and BEL7404 ( F ) cells to Talazoparib. shLuc was used as a non-targeted control. A – F The cell lines were treated with indicated drugs and allowed to grow for 6 days. Cell viability was assessed by the Cell Titer-Glo assay. Surviving fractions were calculated relative to control untreated cells. All dots and error bars represent means ± SDs from at least three independent experiments. Statistical analyses were performed using two-way ANOVA testing. G Schematic illustration of the treatment protocol in the OC316 xenograft model. H Tumor growth curves of OC316 xenograft tumor-bearing mice for each indicated group ( n = 5). Significance was determined by an unpaired t-test at the endpoint. Error bars show ±1 SEM. I Tumor weight measurement at the endpoint of ( G ). Significance was determined by an unpaired t -test. Error bars show ±1 SD. J Images of dissected tumor tissues for each indicated group. ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

    Article Snippet: Following primary antibodies were used for western blot analysis in this study: FLAG (GNI, Cat# GNI4110-FG), Myc (Cell Signaling, Cat# 2276S), GAPDH (Proteintech, Cat# 10494-1-AP-100UL), γ-tubulin (Sigma-Aldrich, Cat# T6557), Vinculin (Sigma, Cat# V4505), PINX1 (Proteintech, Cat# 12368-1-AP-50ul), PAR (R&D, Cat# 4335-MC-100), PARP1 (Cell Signaling, Cat# 9542S), Lamin B1 (Bimake, Cat# A5106), β-tubulin (Eastacres Biologicals, Cat# MaTub-b), XRCC1 (Bimake, Cat# A5299), PCNA (Santa Cruz, Cat# sc-7907), γH2AX (Millipore, Cat# 05-636), Histone H3 (Bimake, Cat# A5885), Lamin B (Santa Cruz, Cat# sc-6216), FLAG (Abclonal, Cat# AE063), Myc (Abclonal, Cat# AE070), UTP14A (Abclonal, Cat# A5960), ZNF24 (Santa Cruz, Cat# sc-393359), ATM (Beyotime, Cat# AF1399), ATM p-Ser1981 (Abclonal, Cat# AP0008), ATR (Beyotime, Cat# AF6267), ATR p-Thr1989 (GeneTex, Cat# GTX637560-S), GFP (BBI, Cat# D110008), mCherry (OriGene, Cat# AB8181-200).

    Techniques: Clone Assay, Derivative Assay, Stable Transfection, Plasmid Preparation, Knockdown, Control, Glo Assay

    A Sensitivity of WT, PINX1 KO , and PARP1 KO PINX1 KO Hela cells to etoposide. B Sensitivity of indicated Hela cell lines to etoposide. PINX1 KO _EV, PINX1 KO _PINX1, and PINX1 KO _PINX1[1–253aa] are stable cell lines reconstituted with corresponding empty vector (EV), full-length PINX1 or TID domain truncated PINX1 (PINX1[1–253aa]) using lentivirus. A , B The cell lines were treated with indicated drugs and allowed to grow for 6 days. Cell viability was assessed by the Cell Titer-Glo assay. Surviving fractions were calculated relative to control untreated cells. All dots and error bars represent means ± SDs from at least three independent experiments. Statistical analyses were performed using two-way ANOVA testing. C Unrepaired DNA strand breaks quantified by alkaline comet assays in the WT and the indicated gene-edited Hela cell lines following treatment with 10 µM etoposide for 30 min and recovery for 30 min. Data plotted are the individual comet tail moments (an arbitrary measure of DNA strand breakage) of ≥116 cells per condition normalized to corresponding no-treatment control (NTC) cells. Significance was determined by an unpaired t -test. Error bars show ±1 SEM. D Representative images of the levels of γH2AX in WT, PARP1 KO , PINX1 KO , and PARP1 KO PINX1 KO Hela cells upon treatment with 10 µM etoposide for 30 min and recovery for 3 h. Red, γH2AX; blue, DAPI. Scale bar, 20 μm. E Measurement of remaining γH2AX levels in WT, PARP1 KO , PINX1 KO, and PARP1 KO PINX1 KO Hela cells by immunofluorescence upon treatment with 10 µM etoposide for 30 min and recovery for 3 h. γH2AX intensity was normalized to 0 for untreated cells and 100% for cells without recovery in each cell line. More than 65 cells were analyzed per condition. Significance was determined by an unpaired t-test. Error bars show ±1 SEM. ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells

    doi: 10.1038/s41419-024-07009-6

    Figure Lengend Snippet: A Sensitivity of WT, PINX1 KO , and PARP1 KO PINX1 KO Hela cells to etoposide. B Sensitivity of indicated Hela cell lines to etoposide. PINX1 KO _EV, PINX1 KO _PINX1, and PINX1 KO _PINX1[1–253aa] are stable cell lines reconstituted with corresponding empty vector (EV), full-length PINX1 or TID domain truncated PINX1 (PINX1[1–253aa]) using lentivirus. A , B The cell lines were treated with indicated drugs and allowed to grow for 6 days. Cell viability was assessed by the Cell Titer-Glo assay. Surviving fractions were calculated relative to control untreated cells. All dots and error bars represent means ± SDs from at least three independent experiments. Statistical analyses were performed using two-way ANOVA testing. C Unrepaired DNA strand breaks quantified by alkaline comet assays in the WT and the indicated gene-edited Hela cell lines following treatment with 10 µM etoposide for 30 min and recovery for 30 min. Data plotted are the individual comet tail moments (an arbitrary measure of DNA strand breakage) of ≥116 cells per condition normalized to corresponding no-treatment control (NTC) cells. Significance was determined by an unpaired t -test. Error bars show ±1 SEM. D Representative images of the levels of γH2AX in WT, PARP1 KO , PINX1 KO , and PARP1 KO PINX1 KO Hela cells upon treatment with 10 µM etoposide for 30 min and recovery for 3 h. Red, γH2AX; blue, DAPI. Scale bar, 20 μm. E Measurement of remaining γH2AX levels in WT, PARP1 KO , PINX1 KO, and PARP1 KO PINX1 KO Hela cells by immunofluorescence upon treatment with 10 µM etoposide for 30 min and recovery for 3 h. γH2AX intensity was normalized to 0 for untreated cells and 100% for cells without recovery in each cell line. More than 65 cells were analyzed per condition. Significance was determined by an unpaired t-test. Error bars show ±1 SEM. ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

    Article Snippet: Following primary antibodies were used for western blot analysis in this study: FLAG (GNI, Cat# GNI4110-FG), Myc (Cell Signaling, Cat# 2276S), GAPDH (Proteintech, Cat# 10494-1-AP-100UL), γ-tubulin (Sigma-Aldrich, Cat# T6557), Vinculin (Sigma, Cat# V4505), PINX1 (Proteintech, Cat# 12368-1-AP-50ul), PAR (R&D, Cat# 4335-MC-100), PARP1 (Cell Signaling, Cat# 9542S), Lamin B1 (Bimake, Cat# A5106), β-tubulin (Eastacres Biologicals, Cat# MaTub-b), XRCC1 (Bimake, Cat# A5299), PCNA (Santa Cruz, Cat# sc-7907), γH2AX (Millipore, Cat# 05-636), Histone H3 (Bimake, Cat# A5885), Lamin B (Santa Cruz, Cat# sc-6216), FLAG (Abclonal, Cat# AE063), Myc (Abclonal, Cat# AE070), UTP14A (Abclonal, Cat# A5960), ZNF24 (Santa Cruz, Cat# sc-393359), ATM (Beyotime, Cat# AF1399), ATM p-Ser1981 (Abclonal, Cat# AP0008), ATR (Beyotime, Cat# AF6267), ATR p-Thr1989 (GeneTex, Cat# GTX637560-S), GFP (BBI, Cat# D110008), mCherry (OriGene, Cat# AB8181-200).

    Techniques: Stable Transfection, Plasmid Preparation, Glo Assay, Control, Immunofluorescence

    A Representative images of the recruitment of indicated proteins to the laser-induced DNA damage sites. U2OS cells were co-transfected with PARP1–EGFP and PINX1/UTP14A/ZNF24–FLAG constructs, pre-sensitized with Hoechst 33342 before micro-irradiation with a 405 nm laser, and subjected to immunostaining with an anti-FLAG antibody. The enrichment of PARP1–EGFP was used to track the DNA damage sites, and PCNA was used as a positive control for the immunostaining. Red, FLAG; green, EGFP; blue, Hoechst 33342. Scale bar, 10 μm. B , C Recruitment kinetics of PINX1-mCherry ( B ) and PARP1-EGFP ( C ) to DNA lesions in Hela cells. Hela cells were co-transfected with PINX1-mCherry and PARP1-EGFP constructs and pre-sensitized with Hoechst 33342 before micro-irradiation coupled live-cell imaging. Seventeen nuclei were analyzed, and the intensity of the damaged region was normalized to that of the undamaged region for the relative recruitment. The vertical dotted line indicates the time of laser stimulation. Curves are shown as means ± SEMs. D Violin plot of Pearson’s R value of colocalization between PINX1–EGFP and γH2AX at indicated time points after laser-induced DNA damage. Hela cells were transfected with PINX1–EGFP and subjected to micro-irradiation as described in Methods and fixed at different time points for immunostaining of γH2AX. More than twenty-nine cells were analyzed per condition. E Representative images of the recruitment of PINX1-mCherry to the laser-induced DNA damage sites in PARP1 KO PINX1 KO Hela cells transfected with a PARP1 construct (+PARP1) or corresponding empty vector (+EV). Laser stimulation was performed at 10 s. Scale bar, 10 μm. F Recruitment kinetics of PINX1-mCherry to the laser-induced DNA damage sites in PARP1 KO PINX1 KO Hela cells transfected with a PARP1 construct (+PARP1) or corresponding empty vector (+EV). More than sixty nuclei were analyzed per condition. The vertical dotted line indicates the time of laser stimulation. Curves are shown as means ± SEMs. Statistical analyses were performed using two-way ANOVA testing. G Representative images of the recruitment of XRCC1–EGFP to the laser-induced DNA damage sites in WT_EV (WT), PINX1 KO _EV (PINX1 KO ), PINX1 KO _PINX1 Hela cells. Laser stimulation was performed at 10 s. Scale bar, 10 μm. H Recruitment kinetics of XRCC1–EGFP to the laser-induced DNA damage sites in WT_EV (WT), PINX1 KO _EV (PINX1 KO ), PINX1 KO _PINX1 Hela cells. More than 31 nuclei were analyzed per condition. The vertical dotted line indicates the time of laser stimulation. Curves are shown as means ± SEMs. Statistical analyses were performed using two-way ANOVA testing. ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells

    doi: 10.1038/s41419-024-07009-6

    Figure Lengend Snippet: A Representative images of the recruitment of indicated proteins to the laser-induced DNA damage sites. U2OS cells were co-transfected with PARP1–EGFP and PINX1/UTP14A/ZNF24–FLAG constructs, pre-sensitized with Hoechst 33342 before micro-irradiation with a 405 nm laser, and subjected to immunostaining with an anti-FLAG antibody. The enrichment of PARP1–EGFP was used to track the DNA damage sites, and PCNA was used as a positive control for the immunostaining. Red, FLAG; green, EGFP; blue, Hoechst 33342. Scale bar, 10 μm. B , C Recruitment kinetics of PINX1-mCherry ( B ) and PARP1-EGFP ( C ) to DNA lesions in Hela cells. Hela cells were co-transfected with PINX1-mCherry and PARP1-EGFP constructs and pre-sensitized with Hoechst 33342 before micro-irradiation coupled live-cell imaging. Seventeen nuclei were analyzed, and the intensity of the damaged region was normalized to that of the undamaged region for the relative recruitment. The vertical dotted line indicates the time of laser stimulation. Curves are shown as means ± SEMs. D Violin plot of Pearson’s R value of colocalization between PINX1–EGFP and γH2AX at indicated time points after laser-induced DNA damage. Hela cells were transfected with PINX1–EGFP and subjected to micro-irradiation as described in Methods and fixed at different time points for immunostaining of γH2AX. More than twenty-nine cells were analyzed per condition. E Representative images of the recruitment of PINX1-mCherry to the laser-induced DNA damage sites in PARP1 KO PINX1 KO Hela cells transfected with a PARP1 construct (+PARP1) or corresponding empty vector (+EV). Laser stimulation was performed at 10 s. Scale bar, 10 μm. F Recruitment kinetics of PINX1-mCherry to the laser-induced DNA damage sites in PARP1 KO PINX1 KO Hela cells transfected with a PARP1 construct (+PARP1) or corresponding empty vector (+EV). More than sixty nuclei were analyzed per condition. The vertical dotted line indicates the time of laser stimulation. Curves are shown as means ± SEMs. Statistical analyses were performed using two-way ANOVA testing. G Representative images of the recruitment of XRCC1–EGFP to the laser-induced DNA damage sites in WT_EV (WT), PINX1 KO _EV (PINX1 KO ), PINX1 KO _PINX1 Hela cells. Laser stimulation was performed at 10 s. Scale bar, 10 μm. H Recruitment kinetics of XRCC1–EGFP to the laser-induced DNA damage sites in WT_EV (WT), PINX1 KO _EV (PINX1 KO ), PINX1 KO _PINX1 Hela cells. More than 31 nuclei were analyzed per condition. The vertical dotted line indicates the time of laser stimulation. Curves are shown as means ± SEMs. Statistical analyses were performed using two-way ANOVA testing. ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

    Article Snippet: Following primary antibodies were used for western blot analysis in this study: FLAG (GNI, Cat# GNI4110-FG), Myc (Cell Signaling, Cat# 2276S), GAPDH (Proteintech, Cat# 10494-1-AP-100UL), γ-tubulin (Sigma-Aldrich, Cat# T6557), Vinculin (Sigma, Cat# V4505), PINX1 (Proteintech, Cat# 12368-1-AP-50ul), PAR (R&D, Cat# 4335-MC-100), PARP1 (Cell Signaling, Cat# 9542S), Lamin B1 (Bimake, Cat# A5106), β-tubulin (Eastacres Biologicals, Cat# MaTub-b), XRCC1 (Bimake, Cat# A5299), PCNA (Santa Cruz, Cat# sc-7907), γH2AX (Millipore, Cat# 05-636), Histone H3 (Bimake, Cat# A5885), Lamin B (Santa Cruz, Cat# sc-6216), FLAG (Abclonal, Cat# AE063), Myc (Abclonal, Cat# AE070), UTP14A (Abclonal, Cat# A5960), ZNF24 (Santa Cruz, Cat# sc-393359), ATM (Beyotime, Cat# AF1399), ATM p-Ser1981 (Abclonal, Cat# AP0008), ATR (Beyotime, Cat# AF6267), ATR p-Thr1989 (GeneTex, Cat# GTX637560-S), GFP (BBI, Cat# D110008), mCherry (OriGene, Cat# AB8181-200).

    Techniques: Transfection, Construct, Irradiation, Immunostaining, Positive Control, Live Cell Imaging, Plasmid Preparation

    A The schematic diagram of PARP1 motifs and mutants used for domain mapping and the summary of their binding ability with PINX1. Numbers indicate the respective amino acid positions. B Effect of PARP activation or inhibition on the association between PARP1 and PINX1. PINX1–FLAG was co-transfected with PARP1-Myc into HEK293T cells. Cells were pre-treated with DMSO or 1 µM Olaparib for 40 min before treatment with 50 µM MNNG for 15 min or 2 mM H 2 O 2 for 5 min. IP of whole cell lysates with anti-FLAG agarose beads was performed.

    Journal: Cell Death & Disease

    Article Title: PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells

    doi: 10.1038/s41419-024-07009-6

    Figure Lengend Snippet: A The schematic diagram of PARP1 motifs and mutants used for domain mapping and the summary of their binding ability with PINX1. Numbers indicate the respective amino acid positions. B Effect of PARP activation or inhibition on the association between PARP1 and PINX1. PINX1–FLAG was co-transfected with PARP1-Myc into HEK293T cells. Cells were pre-treated with DMSO or 1 µM Olaparib for 40 min before treatment with 50 µM MNNG for 15 min or 2 mM H 2 O 2 for 5 min. IP of whole cell lysates with anti-FLAG agarose beads was performed.

    Article Snippet: Following primary antibodies were used for western blot analysis in this study: FLAG (GNI, Cat# GNI4110-FG), Myc (Cell Signaling, Cat# 2276S), GAPDH (Proteintech, Cat# 10494-1-AP-100UL), γ-tubulin (Sigma-Aldrich, Cat# T6557), Vinculin (Sigma, Cat# V4505), PINX1 (Proteintech, Cat# 12368-1-AP-50ul), PAR (R&D, Cat# 4335-MC-100), PARP1 (Cell Signaling, Cat# 9542S), Lamin B1 (Bimake, Cat# A5106), β-tubulin (Eastacres Biologicals, Cat# MaTub-b), XRCC1 (Bimake, Cat# A5299), PCNA (Santa Cruz, Cat# sc-7907), γH2AX (Millipore, Cat# 05-636), Histone H3 (Bimake, Cat# A5885), Lamin B (Santa Cruz, Cat# sc-6216), FLAG (Abclonal, Cat# AE063), Myc (Abclonal, Cat# AE070), UTP14A (Abclonal, Cat# A5960), ZNF24 (Santa Cruz, Cat# sc-393359), ATM (Beyotime, Cat# AF1399), ATM p-Ser1981 (Abclonal, Cat# AP0008), ATR (Beyotime, Cat# AF6267), ATR p-Thr1989 (GeneTex, Cat# GTX637560-S), GFP (BBI, Cat# D110008), mCherry (OriGene, Cat# AB8181-200).

    Techniques: Binding Assay, Activation Assay, Inhibition, Transfection

    A Chromatin fractionation of WT, PINX1 KO , and PARP1 KO cells was treated with 10 µM etoposide for 30 min and recovered for the indicated time. Soluble and chromatin fractions were subjected to western blot analysis using the indicated antibodies. B Chromatin fractionation of WT_EV (WT), PINX1 KO _EV (PINX1 KO ), and PINX1 KO _PINX1 cells treated with DMSO or 10 µM for 1 h. Whole-cell lysates (WCL) and chromatin fractions were subjected to western blot analysis using the indicated antibodies. The data are representative of two independent experiments. C–F mRNA levels of XRCC1 ( C ), PCNA ( D ), ATM ( E ), and ATR ( F ) in WT_EV, PINX1 KO _EV, and PINX1 KO _PINX1 cells. mRNA expression was measured by qRT-PCR. Error bars show the means ± SDs of samples from at least three replicates, using GAPDH as an endogenous control. G WT_EV, PINX1 KO _EV, and PINX1 KO _PINX1 cells were treated with 10 μM of etoposide for 17 h and lysed for WB analysis. H WT_EV, PINX1 KO _EV, and PINX1 KO _PINX1 cells were treated with 4 mM of hydroxyurea (HU) for 23 h and lysed for WB analysis. Significance was determined by an unpaired t -test. ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells

    doi: 10.1038/s41419-024-07009-6

    Figure Lengend Snippet: A Chromatin fractionation of WT, PINX1 KO , and PARP1 KO cells was treated with 10 µM etoposide for 30 min and recovered for the indicated time. Soluble and chromatin fractions were subjected to western blot analysis using the indicated antibodies. B Chromatin fractionation of WT_EV (WT), PINX1 KO _EV (PINX1 KO ), and PINX1 KO _PINX1 cells treated with DMSO or 10 µM for 1 h. Whole-cell lysates (WCL) and chromatin fractions were subjected to western blot analysis using the indicated antibodies. The data are representative of two independent experiments. C–F mRNA levels of XRCC1 ( C ), PCNA ( D ), ATM ( E ), and ATR ( F ) in WT_EV, PINX1 KO _EV, and PINX1 KO _PINX1 cells. mRNA expression was measured by qRT-PCR. Error bars show the means ± SDs of samples from at least three replicates, using GAPDH as an endogenous control. G WT_EV, PINX1 KO _EV, and PINX1 KO _PINX1 cells were treated with 10 μM of etoposide for 17 h and lysed for WB analysis. H WT_EV, PINX1 KO _EV, and PINX1 KO _PINX1 cells were treated with 4 mM of hydroxyurea (HU) for 23 h and lysed for WB analysis. Significance was determined by an unpaired t -test. ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

    Article Snippet: Following primary antibodies were used for western blot analysis in this study: FLAG (GNI, Cat# GNI4110-FG), Myc (Cell Signaling, Cat# 2276S), GAPDH (Proteintech, Cat# 10494-1-AP-100UL), γ-tubulin (Sigma-Aldrich, Cat# T6557), Vinculin (Sigma, Cat# V4505), PINX1 (Proteintech, Cat# 12368-1-AP-50ul), PAR (R&D, Cat# 4335-MC-100), PARP1 (Cell Signaling, Cat# 9542S), Lamin B1 (Bimake, Cat# A5106), β-tubulin (Eastacres Biologicals, Cat# MaTub-b), XRCC1 (Bimake, Cat# A5299), PCNA (Santa Cruz, Cat# sc-7907), γH2AX (Millipore, Cat# 05-636), Histone H3 (Bimake, Cat# A5885), Lamin B (Santa Cruz, Cat# sc-6216), FLAG (Abclonal, Cat# AE063), Myc (Abclonal, Cat# AE070), UTP14A (Abclonal, Cat# A5960), ZNF24 (Santa Cruz, Cat# sc-393359), ATM (Beyotime, Cat# AF1399), ATM p-Ser1981 (Abclonal, Cat# AP0008), ATR (Beyotime, Cat# AF6267), ATR p-Thr1989 (GeneTex, Cat# GTX637560-S), GFP (BBI, Cat# D110008), mCherry (OriGene, Cat# AB8181-200).

    Techniques: Fractionation, Western Blot, Expressing, Quantitative RT-PCR, Control

    A Volcano plot of differential PARP1 binding peaks between PINX1 KO _EV and WT_EV cells. ChIP-seq was performed using an anti-PARP1 antibody. The differential peaks were determined by more than 2-fold change in read counts and p -value ≤ 0.05. Red dots represent a total of 241 upregulated PARP1 binding peaks (Up: 241), blue dots represent a total of 216 downregulated PARP1 binding peaks (Down: 216), gray dots are nonsignificant peaks (No Significant), and differential PARP1 binding peaks adjacent to genes involved in protein expression regulation were labeled and marked by stars. B Volcano plot of differential PARP1 binding peaks between PINX1 KO _PINX1 and PINX1 KO _EV cells. ChIP-seq was performed using an anti-PARP1 antibody. The differential peaks were determined by more than 2-fold change in read counts and p -value ≤ 0.05. Red dots represent a total of 235 upregulated PARP1 binding peaks (Up: 235), blue dots represent a total of 244 downregulated PARP1 binding peaks (Down: 244), gray dots are nonsignificant peaks (No Significant), and differential PARP1 binding peaks adjacent to genes involved in protein expression regulation were labeled and marked by stars. C mRNA levels of genes with differential PARP1 binding upon PINX1 depletion in WT_EV, PINX1 KO _EV, PINX1 KO _PINX1 cells. mRNA expression was measured by qRT-PCR. Error bars show the means ± SDs of samples from at least three replicates, using GAPDH as an endogenous control. Significance was determined by an unpaired t -test. D GLIS3 supplementation in PINX1 KO cells partially rescued the susceptibility to Talazoparib. PINX1 KO _EV, PINX1 KO _GLIS3, and PINX1 KO _PINX1 are stable cell lines reconstituted with corresponding empty vector (EV), GLIS3, or PINX1 using lentivirus. E HNF4G supplementation in PINX1 KO cells partially rescued the susceptibility to Talazoparib. PINX1 KO _EV, PINX1 KO _HNF4G, and PINX1 KO _PINX1 are stable cell lines reconstituted with corresponding empty vector (EV), HNF4G, or PINX1 using lentivirus. Error bars show the means ± SDs of samples from at least three replicates. Significance was determined by an unpaired t -test. ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells

    doi: 10.1038/s41419-024-07009-6

    Figure Lengend Snippet: A Volcano plot of differential PARP1 binding peaks between PINX1 KO _EV and WT_EV cells. ChIP-seq was performed using an anti-PARP1 antibody. The differential peaks were determined by more than 2-fold change in read counts and p -value ≤ 0.05. Red dots represent a total of 241 upregulated PARP1 binding peaks (Up: 241), blue dots represent a total of 216 downregulated PARP1 binding peaks (Down: 216), gray dots are nonsignificant peaks (No Significant), and differential PARP1 binding peaks adjacent to genes involved in protein expression regulation were labeled and marked by stars. B Volcano plot of differential PARP1 binding peaks between PINX1 KO _PINX1 and PINX1 KO _EV cells. ChIP-seq was performed using an anti-PARP1 antibody. The differential peaks were determined by more than 2-fold change in read counts and p -value ≤ 0.05. Red dots represent a total of 235 upregulated PARP1 binding peaks (Up: 235), blue dots represent a total of 244 downregulated PARP1 binding peaks (Down: 244), gray dots are nonsignificant peaks (No Significant), and differential PARP1 binding peaks adjacent to genes involved in protein expression regulation were labeled and marked by stars. C mRNA levels of genes with differential PARP1 binding upon PINX1 depletion in WT_EV, PINX1 KO _EV, PINX1 KO _PINX1 cells. mRNA expression was measured by qRT-PCR. Error bars show the means ± SDs of samples from at least three replicates, using GAPDH as an endogenous control. Significance was determined by an unpaired t -test. D GLIS3 supplementation in PINX1 KO cells partially rescued the susceptibility to Talazoparib. PINX1 KO _EV, PINX1 KO _GLIS3, and PINX1 KO _PINX1 are stable cell lines reconstituted with corresponding empty vector (EV), GLIS3, or PINX1 using lentivirus. E HNF4G supplementation in PINX1 KO cells partially rescued the susceptibility to Talazoparib. PINX1 KO _EV, PINX1 KO _HNF4G, and PINX1 KO _PINX1 are stable cell lines reconstituted with corresponding empty vector (EV), HNF4G, or PINX1 using lentivirus. Error bars show the means ± SDs of samples from at least three replicates. Significance was determined by an unpaired t -test. ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

    Article Snippet: Following primary antibodies were used for western blot analysis in this study: FLAG (GNI, Cat# GNI4110-FG), Myc (Cell Signaling, Cat# 2276S), GAPDH (Proteintech, Cat# 10494-1-AP-100UL), γ-tubulin (Sigma-Aldrich, Cat# T6557), Vinculin (Sigma, Cat# V4505), PINX1 (Proteintech, Cat# 12368-1-AP-50ul), PAR (R&D, Cat# 4335-MC-100), PARP1 (Cell Signaling, Cat# 9542S), Lamin B1 (Bimake, Cat# A5106), β-tubulin (Eastacres Biologicals, Cat# MaTub-b), XRCC1 (Bimake, Cat# A5299), PCNA (Santa Cruz, Cat# sc-7907), γH2AX (Millipore, Cat# 05-636), Histone H3 (Bimake, Cat# A5885), Lamin B (Santa Cruz, Cat# sc-6216), FLAG (Abclonal, Cat# AE063), Myc (Abclonal, Cat# AE070), UTP14A (Abclonal, Cat# A5960), ZNF24 (Santa Cruz, Cat# sc-393359), ATM (Beyotime, Cat# AF1399), ATM p-Ser1981 (Abclonal, Cat# AP0008), ATR (Beyotime, Cat# AF6267), ATR p-Thr1989 (GeneTex, Cat# GTX637560-S), GFP (BBI, Cat# D110008), mCherry (OriGene, Cat# AB8181-200).

    Techniques: Binding Assay, ChIP-sequencing, Expressing, Labeling, Quantitative RT-PCR, Control, Stable Transfection, Plasmid Preparation

    PINX1 acts as a multifaceted partner of PARP1 that promotes cellular response to DNA damage and PARP inhibitors. Under normal conditions, PINX1 constitutively binds to PARP1, aiding in chromatin association and transcriptional regulation of PARP1, enhancing the expression of DNA repair genes such as XRCC1 and transcriptional regulatory factors such as GLIS3, ensuring cellular DNA damage repair capacity. At the time of DNA damage, PINX1 is rapidly recruited to the damage sites via PARP1, facilitating the recruitment of early repair factor XRCC1 and downstream DNA repair processes. Both mechanisms contribute to cellular defense against PARP inhibitors.

    Journal: Cell Death & Disease

    Article Title: PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells

    doi: 10.1038/s41419-024-07009-6

    Figure Lengend Snippet: PINX1 acts as a multifaceted partner of PARP1 that promotes cellular response to DNA damage and PARP inhibitors. Under normal conditions, PINX1 constitutively binds to PARP1, aiding in chromatin association and transcriptional regulation of PARP1, enhancing the expression of DNA repair genes such as XRCC1 and transcriptional regulatory factors such as GLIS3, ensuring cellular DNA damage repair capacity. At the time of DNA damage, PINX1 is rapidly recruited to the damage sites via PARP1, facilitating the recruitment of early repair factor XRCC1 and downstream DNA repair processes. Both mechanisms contribute to cellular defense against PARP inhibitors.

    Article Snippet: Following primary antibodies were used for western blot analysis in this study: FLAG (GNI, Cat# GNI4110-FG), Myc (Cell Signaling, Cat# 2276S), GAPDH (Proteintech, Cat# 10494-1-AP-100UL), γ-tubulin (Sigma-Aldrich, Cat# T6557), Vinculin (Sigma, Cat# V4505), PINX1 (Proteintech, Cat# 12368-1-AP-50ul), PAR (R&D, Cat# 4335-MC-100), PARP1 (Cell Signaling, Cat# 9542S), Lamin B1 (Bimake, Cat# A5106), β-tubulin (Eastacres Biologicals, Cat# MaTub-b), XRCC1 (Bimake, Cat# A5299), PCNA (Santa Cruz, Cat# sc-7907), γH2AX (Millipore, Cat# 05-636), Histone H3 (Bimake, Cat# A5885), Lamin B (Santa Cruz, Cat# sc-6216), FLAG (Abclonal, Cat# AE063), Myc (Abclonal, Cat# AE070), UTP14A (Abclonal, Cat# A5960), ZNF24 (Santa Cruz, Cat# sc-393359), ATM (Beyotime, Cat# AF1399), ATM p-Ser1981 (Abclonal, Cat# AP0008), ATR (Beyotime, Cat# AF6267), ATR p-Thr1989 (GeneTex, Cat# GTX637560-S), GFP (BBI, Cat# D110008), mCherry (OriGene, Cat# AB8181-200).

    Techniques: Expressing

     PINX1  expression and correlation between papillary and anaplastic thyroid carcinoma

    Journal: American Journal of Cancer Research

    Article Title: PINX1 promotes malignant transformation of thyroid cancer through the activation of the AKT/MAPK/β-catenin signaling pathway

    doi:

    Figure Lengend Snippet: PINX1 expression and correlation between papillary and anaplastic thyroid carcinoma

    Article Snippet: PINX1 antibody (12368-1-AP; Proteintech, Rosemont, IL, USA, 1:100) was treated and incubated for 60 min at RT.

    Techniques: Expressing

    The higher expression of PINX1 in ATC than in PTC. A. Relative mRNA expression levels of PINX1 in patient tissues. Total RNA was isolated from FFPE thyroid cancer tissues, which were proceeded in real-time qRT-PCR. B. Immunohistochemistry (IHC) in papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC) patient tissues. Representative negative and positive IHC staining images of PINX1 are shown. Scale bars represent 100 μm. C. The levels of PINX1 expression in normal thyroid cell line and thyroid cancer cell lines were investigated by real-time qRT-PCR. Nthy-ori 3-1 cell was selected for normal thyroid cell line, BCPAP and SNU-790 cells were used for representative PTC cell lines, and 8505C and SNU-80 cells were selected for ATC cell lines. P values were determined by one-way ANOVA. (****: P<0.0001). D. PINX1 expression was confirmed in normal thyroid, PTC and ATC cell lines. The level of β-actin is used as internal quantitative control.

    Journal: American Journal of Cancer Research

    Article Title: PINX1 promotes malignant transformation of thyroid cancer through the activation of the AKT/MAPK/β-catenin signaling pathway

    doi:

    Figure Lengend Snippet: The higher expression of PINX1 in ATC than in PTC. A. Relative mRNA expression levels of PINX1 in patient tissues. Total RNA was isolated from FFPE thyroid cancer tissues, which were proceeded in real-time qRT-PCR. B. Immunohistochemistry (IHC) in papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC) patient tissues. Representative negative and positive IHC staining images of PINX1 are shown. Scale bars represent 100 μm. C. The levels of PINX1 expression in normal thyroid cell line and thyroid cancer cell lines were investigated by real-time qRT-PCR. Nthy-ori 3-1 cell was selected for normal thyroid cell line, BCPAP and SNU-790 cells were used for representative PTC cell lines, and 8505C and SNU-80 cells were selected for ATC cell lines. P values were determined by one-way ANOVA. (****: P<0.0001). D. PINX1 expression was confirmed in normal thyroid, PTC and ATC cell lines. The level of β-actin is used as internal quantitative control.

    Article Snippet: PINX1 antibody (12368-1-AP; Proteintech, Rosemont, IL, USA, 1:100) was treated and incubated for 60 min at RT.

    Techniques: Expressing, Isolation, Quantitative RT-PCR, Immunohistochemistry

    PINX1 promotes the proliferation of thyroid cancer cells. (A and B) The expression levels of PINX1 were assessed after PINX1 gene regulation. The decrease in PINX1 expression after PINX1 knockdown in ATC cell lines (A) and the increase in PINX1 levels after PINX1 overexpression in PTC cell lines (B) were confirmed by western blotting. (C and D) The effect of PINX1 regulation on cell proliferation was analyzed by a proliferation assay. 1.0 × 104 cells were seeded after PINX1 downregulation (C) or PINX1 overexpression (D), and the number of cells was checked for every 24 h. P values were determined by two-way ANOVA. (***: P<0.001). (E and F) The effect of gene regulation of PINX1 on cell proliferation was examined by colony formation assay. (G and H) Effect of PINX1 knockdown or PINX1 overexpression on cell cycle progression was assessed with flow cytometry after PI staining.

    Journal: American Journal of Cancer Research

    Article Title: PINX1 promotes malignant transformation of thyroid cancer through the activation of the AKT/MAPK/β-catenin signaling pathway

    doi:

    Figure Lengend Snippet: PINX1 promotes the proliferation of thyroid cancer cells. (A and B) The expression levels of PINX1 were assessed after PINX1 gene regulation. The decrease in PINX1 expression after PINX1 knockdown in ATC cell lines (A) and the increase in PINX1 levels after PINX1 overexpression in PTC cell lines (B) were confirmed by western blotting. (C and D) The effect of PINX1 regulation on cell proliferation was analyzed by a proliferation assay. 1.0 × 104 cells were seeded after PINX1 downregulation (C) or PINX1 overexpression (D), and the number of cells was checked for every 24 h. P values were determined by two-way ANOVA. (***: P<0.001). (E and F) The effect of gene regulation of PINX1 on cell proliferation was examined by colony formation assay. (G and H) Effect of PINX1 knockdown or PINX1 overexpression on cell cycle progression was assessed with flow cytometry after PI staining.

    Article Snippet: PINX1 antibody (12368-1-AP; Proteintech, Rosemont, IL, USA, 1:100) was treated and incubated for 60 min at RT.

    Techniques: Expressing, Over Expression, Western Blot, Proliferation Assay, Colony Assay, Flow Cytometry, Staining

    PINX1 promotes cell migration and EMT in vitro. (A-D) The effect of PINX1 downregulation and PINX1 overexpression on cell motility was assessed with the transwell migration assay. Representative images of cell migration after PINX1 gene regulation are shown in (A and C). The relative cell counts in the migrated area of transwell are shown in (B and D). (E) Wound healing capacity after PINX1 knockdown was checked in 8505C and SNU-80 cell lines. (F and G) Effect of PINX1 knockdown or PINX1 upregulation on EMT markers expression was analyzed by western blotting. Statistical analyses were performed by unpaired 2-tailed t test for (B-E) (*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001).

    Journal: American Journal of Cancer Research

    Article Title: PINX1 promotes malignant transformation of thyroid cancer through the activation of the AKT/MAPK/β-catenin signaling pathway

    doi:

    Figure Lengend Snippet: PINX1 promotes cell migration and EMT in vitro. (A-D) The effect of PINX1 downregulation and PINX1 overexpression on cell motility was assessed with the transwell migration assay. Representative images of cell migration after PINX1 gene regulation are shown in (A and C). The relative cell counts in the migrated area of transwell are shown in (B and D). (E) Wound healing capacity after PINX1 knockdown was checked in 8505C and SNU-80 cell lines. (F and G) Effect of PINX1 knockdown or PINX1 upregulation on EMT markers expression was analyzed by western blotting. Statistical analyses were performed by unpaired 2-tailed t test for (B-E) (*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001).

    Article Snippet: PINX1 antibody (12368-1-AP; Proteintech, Rosemont, IL, USA, 1:100) was treated and incubated for 60 min at RT.

    Techniques: Migration, In Vitro, Over Expression, Transwell Migration Assay, Expressing, Western Blot

    PINX1 promotes proliferation and aggressiveness of thyroid cancer cells in mouse xenografts. (A and B) The levels of PINX1 after PINX1 knockdown or overexpression were assessed with western blotting. 8505C and BCPAP cells were used for the mouse xenografts of ATC or PTC cell lines, respectively. (C and D) Effect of PINX1 expression on tumor growth in mice xenografts. The tumor size is shown in (C and E) The volume of xenograft tumor was measured every week. Error bars represent SEM for tumor volume (n=5). Statistical analysis was performed by 2-way ANOVA (*P<0.05; **P<0.01). (E) The effect of PINX1 downregulation or overexpression on tumor proliferation was analyzed by Ki-67 staining. (F and G) The effect of PINX1 regulation on EMT key modulators was examined by western blotting using xenograft tumors.

    Journal: American Journal of Cancer Research

    Article Title: PINX1 promotes malignant transformation of thyroid cancer through the activation of the AKT/MAPK/β-catenin signaling pathway

    doi:

    Figure Lengend Snippet: PINX1 promotes proliferation and aggressiveness of thyroid cancer cells in mouse xenografts. (A and B) The levels of PINX1 after PINX1 knockdown or overexpression were assessed with western blotting. 8505C and BCPAP cells were used for the mouse xenografts of ATC or PTC cell lines, respectively. (C and D) Effect of PINX1 expression on tumor growth in mice xenografts. The tumor size is shown in (C and E) The volume of xenograft tumor was measured every week. Error bars represent SEM for tumor volume (n=5). Statistical analysis was performed by 2-way ANOVA (*P<0.05; **P<0.01). (E) The effect of PINX1 downregulation or overexpression on tumor proliferation was analyzed by Ki-67 staining. (F and G) The effect of PINX1 regulation on EMT key modulators was examined by western blotting using xenograft tumors.

    Article Snippet: PINX1 antibody (12368-1-AP; Proteintech, Rosemont, IL, USA, 1:100) was treated and incubated for 60 min at RT.

    Techniques: Over Expression, Western Blot, Expressing, Staining

    PINX1 activates signaling pathways promoting PTC-to-ATC transition in vitro and in vivo. (A) The relative expression level of PINX1 in patient specimens was compared between ATC and PTC component within a same case. Total RNA was isolated from FFPE samples, which were used for real-time qRT-PCR. Statistical analysis was performed by one-way ANOVA. (ns: not significant; ****P<0.0001). (B and C) Effect of PINX1 gene regulation on PI3K/AKT and MAPK signaling activation was analyzed by western blotting. The phosphorylation levels of AKT, p38, and ERK were assessed after PINX1 downregulation (A) or PINX1 overexpression (B) in vitro. (D and E) Effect of PINX1 knockdown and overexpression on Wnt/β-catenin signaling in vitro was confirmed by western blotting. (F and G) Effect of PINX1 gene expression on PI3K/AKT, MAPKs, and Wnt/β-catenin signaling activation in vivo was confirmed by western blotting of mice xenografts.

    Journal: American Journal of Cancer Research

    Article Title: PINX1 promotes malignant transformation of thyroid cancer through the activation of the AKT/MAPK/β-catenin signaling pathway

    doi:

    Figure Lengend Snippet: PINX1 activates signaling pathways promoting PTC-to-ATC transition in vitro and in vivo. (A) The relative expression level of PINX1 in patient specimens was compared between ATC and PTC component within a same case. Total RNA was isolated from FFPE samples, which were used for real-time qRT-PCR. Statistical analysis was performed by one-way ANOVA. (ns: not significant; ****P<0.0001). (B and C) Effect of PINX1 gene regulation on PI3K/AKT and MAPK signaling activation was analyzed by western blotting. The phosphorylation levels of AKT, p38, and ERK were assessed after PINX1 downregulation (A) or PINX1 overexpression (B) in vitro. (D and E) Effect of PINX1 knockdown and overexpression on Wnt/β-catenin signaling in vitro was confirmed by western blotting. (F and G) Effect of PINX1 gene expression on PI3K/AKT, MAPKs, and Wnt/β-catenin signaling activation in vivo was confirmed by western blotting of mice xenografts.

    Article Snippet: PINX1 antibody (12368-1-AP; Proteintech, Rosemont, IL, USA, 1:100) was treated and incubated for 60 min at RT.

    Techniques: In Vitro, In Vivo, Expressing, Isolation, Quantitative RT-PCR, Activation Assay, Western Blot, Over Expression